Lung Cancer

Lung Cancer Content

touchCLINICAL PERSPECTIVES

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

CE/CME ACCREDITED Dr Helena Yu, Dr Antonio Passaro, Dr Aaron Lisberg, Dr Sara Pilotto, Ms Jackie Fenemore, Prof. Egbert Smit Translations available:

Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.

Learning objectives

Learning Objectives

Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing
Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes
Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes

Lung Cancer

Watch Time: 39 mins

touchMDT

Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors

CE/CME ACCREDITED Dr Lizza Hendriks, Dr Jacob Sands, Prof. Suresh Senan Translations available:

A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).

Learning objectives

Learning Objectives

Evaluate the potential role of immune checkpoint inhibitors in the treatment of patients with limited-stage small cell lung cancer
Recall the latest data for ICIs in LS-SCLC
Examine the possible impact of ICIs on the management of patients with LS-SCLC

Lung Cancer

Watch Time: 55 mins

touchMDT

Precision targeting of MET in NSCLC: A multidisciplinary approach

CE/CME ACCREDITED Dr Xiuning Le, Dr Christine Argento, Dr Sandra Cuellar, Ms Stephanie McDonald, Prof. Albrecht Stenzinger

A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.

Learning objectives

Learning Objectives

Recognize the importance of identifying patients with MET alterations in NSCLC and choose the most appropriate strategy to detect specific gene alterations
Evaluate the evidence from completed or ongoing clinical trials on the use of MET inhibitors in selected patients with advanced NSCLC and implications for future practice
Apply clinical trial data on MET inhibitors in NSCLC, including adverse event management, using an holistic approach to patient care

Lung Cancer

Watch Time: 41 mins

touchPANEL DISCUSSION

Expanding HER2 horizons: Implications for NSCLC and beyond

CE/CME ACCREDITED Dr Razelle Kurzrock, Dr Lyudmila Bazhenova, Dr Ignacio Wistuba Translations available:

Two oncologists and a pathologist discuss the implications of HER2 targeting in solid tumours, with a focus on NSCLC.

Learning objectives

Learning Objectives

Evaluate the clinical implications for tissue-agnostic HER2-targeted treatments for patients with advanced cancer
Discuss the latest data for HER2 targeting therapies in patients with advanced NSCLC and HER2 alterations
Outline best practices and guidelines for biomarker testing to establish HER2 status in patients with advanced NSCLC

Lung Cancer

Watch Time: 37 mins

touchIN CONVERSATION

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

CE/CME ACCREDITED Prof. Enriqueta Felip, Prof. Keith Kerr Translations available:

An oncologist and a pathologist discuss HER2 testing and treatments for HER2-altered NSCLC.

Learning objectives

Learning Objectives

Describe the specific types of HER2 alterations and HER2 testing requirements in NSCLC
Discuss optimal approaches for testing HER2 alterations in NSCLC and implications for their implementation into routine clinical practice
Recall whether HER2 status determines treatment response and outcomes in patients with NSCLC receiving HER2-targeted therapies in NSCLC

Lung Cancer

Watch Time: 33 mins

touchEXPERT OPINIONS

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

CE/CME ACCREDITED Prof. Heather A Wakelee Translations available:

Prof. Wakelee discusses the latest evidence on immunotherapy for early-stage, resectable NSCLC.

Learning objectives

Learning Objectives

Recall the recent advances in immunotherapy for early-stage NSCLC in the neoadjuvant/adjuvant settings
Describe how immunotherapy fits in the treatment algorithm for early-stage NSCLC
Summarize the key eligibility criteria for neoadjuvant/adjuvant immunotherapy, including clinical characteristics and biomarkers

Lung Cancer

Watch Time: 15 mins

touchFOCUS

Current treatments and unmet needs in limited-stage small cell lung cancer

CE/CME ACCREDITED Dr Anne Chiang

A medical oncologist shares her insights on the current treatments for LS-SCLC and the remaining unmet needs

Learning objectives

Learning Objectives

Describe the current treatment landscape for limited-stage small cell lung cancer
Discuss the unmet treatment needs for patients with limited-stage small cell lung cancer

Lung Cancer

Watch Time: 34 minutes

touchTALKS

Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs

CE/CME ACCREDITED Dr Rebecca Heist Translations available:

Dr Rebecca Heist discusses emerging antibody-drug conjugates for the second-line treatment of patients with advanced non-small cell lung cancer.

Learning objectives

Learning Objectives

Recognize the shared mechanisms of action of ADCs and how their different targets and payloads may inform selection in advanced/metastatic NSCLC
Assess the latest clinical trial data for ADCs in patients with advanced/metastatic NSCLC in the second-line setting and identify the advantages and limitations of ADCs
Evaluate how ADCs can be integrated into the treatment pathway for patients with advanced/metastatic NSCLC to facilitate disease management

Lung Cancer

Watch Time: 18 mins

touchFOCUS

Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy

CE/CME ACCREDITED Dr Balazs Halmos

Dr Balazs Halmos offers his perspective on immunotherapy for the treatment of squamous cell lung cancer.

Learning objectives

Learning Objectives

Summarize the key clinical features of advanced squamous cell lung cancer and the challenges they pose to its management
Interpret the most recent clinical data to guide systemic therapy selection for squamous cell lung cancer

Feedback

Feedback

FILTER YOUR SEARCH

Content Type:

Speciality:

Conference:

Lung Cancer

Lung Cancer Content

touchCLINICAL PERSPECTIVES

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

Learning Objectives

touchMDT

Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors

Learning Objectives

touchMDT

Precision targeting of MET in NSCLC: A multidisciplinary approach

Learning Objectives

touchPANEL DISCUSSION

Expanding HER2 horizons: Implications for NSCLC and beyond

Learning Objectives

touchIN CONVERSATION

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

Learning Objectives

touchEXPERT OPINIONS

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

Learning Objectives

touchFOCUS

Current treatments and unmet needs in limited-stage small cell lung cancer

Learning Objectives

touchTALKS

Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs

Learning Objectives

touchFOCUS

Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy

Learning Objectives

Journal articles and more to your inbox

Listen on the go

Share this activity

Feedback

Feedback

Feedback

FILTER YOUR SEARCH

Content Type:

Speciality:

Conference:

Lung Cancer

Lung Cancer Content

touchCLINICAL PERSPECTIVES

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

Learning Objectives

touchMDT

Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors

Learning Objectives

touchMDT

Precision targeting of MET in NSCLC: A multidisciplinary approach

Learning Objectives

touchPANEL DISCUSSION

Expanding HER2 horizons: Implications for NSCLC and beyond

Learning Objectives

touchIN CONVERSATION

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

Learning Objectives

touchEXPERT OPINIONS

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

Learning Objectives

touchFOCUS

Current treatments and unmet needs in limited-stage small cell lung cancer

Learning Objectives

touchTALKS

Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs

Learning Objectives

touchFOCUS

Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy

Learning Objectives

Journal articles and more to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

This Functionality is for
Members Only